What’s Happening With Cannabis Stocks in May 2023?

Cannabis stocks were up this week, as the market began to turn, but how long will it last, and is more growth coming?

| More on:
Cannabis grows at a commercial farm.

Source: Getty Images

It’s starting to look like perhaps cannabis stocks may have hit rock bottom this week. After shares across the board fell lower and lower in 2023, there is a slight uptick recently. But it’s not necessarily due to cannabis stocks themselves.

Market positivity

It seems as though Canadian investors may finally be interested in looking for growth stocks again. Companies continued to hit 52-week lows again and again over the last few months, especially among cannabis stocks. As earnings continue to roll in across the board, however, some investors are jumping on the opportunity to buy low.

This may include those companies in the cannabis market. After hitting 52-week lows, Canopy Growth (TSX:WEED), Tilray (TSX:TLRY), Aurora Cannabis (TSX:ACB) and others all saw an increase in share price. Canopy Growth stock is up 5%, Tilray stock is up 27%, and Aurora stock is up 12% since hitting 52-week lows.

What about the cannabis industry?

News in the cannabis market hasn’t had anything too crazy to allow for a larger increase. However, this could change in the near future. More and more states in the United States continue to climb aboard the cannabis train, with the multi-billion-dollar industry promising more tax incentives and job growth.

In April, Delaware became the 22nd state to legalize recreational marijuana. However, it looks like Ohio, Pennsylvania and Florida may be next on board. This could occur as soon as the end of the year, if perhaps not next year during the next election.

Florida has already been making headlines, as the state recently passed legislation this month to allow medicinal cannabis patients to renew prescriptions through telehealth appointments. While it still needs to run up to the governor, it’s looking promising in such a conservative state.

More movement could come from the Senate soon, as the Secure and Fair Enforcement (SAFE) Banking Act could be passed. This would protect banks that work with cannabis businesses in states where it is legal.

Still a waiting game

Right now, cannabis stocks remain in a waiting game. Each of these companies will continue to have to prove themselves and their path to profits. While Tilray stock remains the only profitable one of the bunch, others may soon climb towards it. But most are awaiting legalization in the United States for that to be a sure thing.

This is why so many cannabis stocks have expanded to other sources of revenue. Tilray stock, for one, now has partnerships for beer production. Canopy Growth stock touts its BioSteel as a huge win. Aurora stock, meanwhile, has remained focused on the marijuana industry, and looks to expand in the medical marijuana sector. However, it’s also had to sell much of its locations and medical marijuana acquisitions to bring in funds.

Bottom line

These cannabis stocks may be on the upswing for now, but it’s still a very volatile market. If you’re interested in cannabis stocks over the long haul, then great! These three cannabis stocks may be a great option.

However, if you’re hoping for a quick turnaround and growth that we saw back in 2018 and 2017, I would hold out longer. We still need a lot of legalization to occur not just around the world but specifically in the United States. This would make the country the largest producer and consumer of marijuana in the world, creating a huge opportunity for investors.

Until then, however, perhaps it’s better to wait on the sidelines.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Amy Legate-Wolfe has positions in Canopy Growth. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

More on Cannabis Stocks

Farmer smiles near cannabis crop
Cannabis Stocks

Can Pot Stocks Aurora Cannabis and Canopy Growth Bounce Back in Q4?

Down over 99% from all-time highs, Canadian pot stocks such as Aurora Cannabis and Canopy Growth remain high-risk bets.

Read more »

Worker tags plants at an industrial cannabis operation
Cannabis Stocks

Can Canopy Growth Stock Finally Recover in 2024?

Down 98% from all-time highs, Canopy Growth remains a high-risk investment in 2024 given its weak fundamentals.

Read more »

A close up image of Canadian $20 Dollar bills
Tech Stocks

3 No-Brainer Stocks to Buy With $20 Right Now

These three stocks are easy buys for those who don't have all that much to spend, and want long-term growth…

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Slow Burn: Is Aurora Cannabis Finally a Good Buy in June?

One of the benefits of choosing from some of the most beaten-down market segments like cannabis is that even a…

Read more »

Caution, careful
Cannabis Stocks

I Wouldn’t Touch This TSX Stock With a 60-Foot Pole

I wouldn't touch Canopy Growth Corp (TSX:WEED) stock with a 60-foot pole.

Read more »

edit Cannabis leaves of a plant on a dark background
Cannabis Stocks

Why This Little-Known Cannabis Stock Could Double in 2024

This cannabis stock has already doubled this year since 52-week lows and could easily rise that much once more.

Read more »

Bad apple with good apples
Cannabis Stocks

1 TSX Stock I Wouldn’t Touch With a 420-Foot Pole

Down 87% from all-time highs, Cronos Group stock is a still a high-risk investment for long-term shareholders in 2024.

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth: Buy, Sell, or Hold?

Canopy Growth (TSX:WEED) stock should make a killing on U.S. expansion, but investors will need to be very patient.

Read more »